Scientific Program
ATTD-ASIA is a groundbreaking expansion of ATTD – the leading international meeting point where clinicians, diabetes care providers, researchers, industries, investors, reimbursement authorities, and people with diabetes assemble with the aim of sharing knowledge and developing collaborations.
Presentations and discussions will be given by many distinguished professionals in the field and will include topics such as digital clinics, decision support systems/advisors, big data and artificial intelligence-based decision support systems, glucose sensors, closed-and open-loop systems, artificial pancreas, devices for diabetic prevention, new insulins and new medications, insulin pumps and many more.
Interactive Program*Program Structure*
*Subject to changes
Session Topics**
- CGM AS THE CORNERSTONE OF DIABETES MANAGEMENT
- CGM IN PRE-T2D AND EARLY T2D
- CLINICAL DECISION SUPPORT SYSTEMS (CDSS) AND APPS
- CLOSED LOOP
- COMBINED GLP1RA AND SGLT2
- COPING WITH OBESITY WITH OR WITHOUT DIABETES
- DIABETES & CVD
- DIABETES & PREGNANCY
- IMPLEMENTING NEW TECHNOLOGIES IN DIABETES MANAGEMENT
- INCRETINS AND THE REMISSION OF DIABETES
- LIFESTYLE MODIFICATIONS RELEVANT TO ASIA (DIET AND EXERCISE OPTIONS)
- MANAGING T2D IN PRIMARY CARE
- PEDIATRIC OBESITY AND DIABETES
- PRE T2D
- PRE-STAGE 3 T1D
- SCREENING PROGRAM AND PREVENTION T1D
- THERAPEUTIC CHOICES FOR OBESITY AND T2D
- TIGHT GLYCEMIC CONTROL
- TRAINING DIABETES TECHNOLOGISTS
- WEEKLY INSULIN
**Topic list as of 21 April 2024
| Ananta | Addala | USA | Solutions for equity: A call to action |
| Peter | Adolfsson | Sweden | Current use of connected pens |
| Stephanie | Amiel | UK | CGM detection of hypoglycemia in diabetes management |
| Lia | Bally | Switzerland | Virtual clinic for insulin therapy in type 2 diabetes |
| Katharine | Barnard-Kelly | UK | Consensus statement summary, navigating the maze of PROs |
| Tadej | Battelino | Slovenia | · CGM derived data on weekly insulins |
| · CGM derived criteria for stage 2 type 1 diabetes | |||
| Richard | Bergenstal | USA | We need to clear the FOG (Feet on the Ground) hyperglycemia in order to minimize hyperglycemia |
| Mithun | Bhartia | India | Diabetes and sex life – the role of technology to improve quality of life |
| Bruce | Bode | USA | Management of glucose in the hospital with AID systems |
| Stefan | Bornstein | Germany | Islet Transplantation 2024 |
| Emanuele | Bosi | Italy | Universal screening for risk of type 1 diabetes: Can it be an effective prevention tool? |
| Charlotte | Boughton | UK | Cumulated experience with CamAPS in type 2 diabetes |
| Nataša | Bratina | Slovenia | Data on diabetes treatment in children below the age of six |
| Raffaella | Buzzetti | Italy | Antibody positivity in adult population |
| Anders | Carlson | USA | · The use of CGM in prediabetes and obesity |
| · Use of AID in patients with type 2 diabetes | |||
| Eda | Cengiz | USA | Update on diabetes Female Technology (femtech) |
| Antonio | Ceriello | Italy | Weight and glycemic variability: Bad companions for CVD development in diabetes |
| Manoj | Chawla | India | Optimizing real time CGM in self pay markets |
| Patrik | Choudhary | UK | Implication of HypoMETRICS for reporting hypoglycemia in clinical trials |
| Mark | Clements | USA | Just in time adaptive interventions: The new technology to “hack” diabetes self-management behavior |
| Xavier | Cos | Spain | Use of CGM by the primary care providers |
| Amy | Criego | USA | CGM Success: Device start and ongoing data management to improve patient care |
| Tali | Cukierman-Yaffe | Israel | · How to measure and monitor sarcopenia and frailty |
| · Diagnosis & monitoring of brain health in people with diabetes | |||
| Thomas | Danne | Germany | Worldwide progress achieving treatment targets in children with type 1 diabetes |
| Christophe | De Block | Belgium | Ketone continuous measurement – Is it needed? |
| Bastiaan | de Galan | The Netherlands | Impaired awareness of hypoglycemia |
| Sergio | di Molfetta | Italy | CGM in type 2 diabetes patients: From professional use to experiences in patients not insulin treated |
| Klemen | Dovc | Slovenia | Automated insulin delivery around exercise in type 1 diabetes: Individualization versus generalizability |
| Celeste | Durnwold | USA | Can CGM replace the oral glucose tolerance test for diagnosis of Gestational diabetes? |
| Steven | Edelman | USA | · Top 10 tips to help people with diabetes (PwD) stay in range |
| · With Jeremy Pettus – Rapid fire interpretations of CGM downloads | |||
| Laya | Ekhlaspour | USA | Beyond carbohydrate counting: Optimizing mealtime insulin dosing |
| Tara | Ettestad | USA | CGM guided or personalized nutrition |
| Chiara | Fabris | USA | · What do women want (and need)? Results from the large-scale IMAGINE survey |
| · Simulation-enhanced closed-loop adaptation of long-acting insulin dosing in T2D | |||
| Leon | Farhy | USA | Diagnostic CGM |
| Andrea | Facchinetti | Italy | Digital twin technologies for treating diabetes |
| Deidre | Fitzgerald-Huges | Ireland | Shining a light on diabetic foot infections, development of novel photodynamic materials |
| Gregory | Forlenza | USA | Real-world data on hybrid closed-loop (HCL) in type 2 diabetes |
| Guido | Freckmann | Germany | International standard for evaluation of CGM systems: Approach of the IFCC |
| Juan | Frias | USA | Update on weekly insulin Efsitora |
| Satish | Garg | USA | Management options for treating obesity in type 1 diabetes patients |
| Michal | Gillon-Keren | Israel | Facilitate carb counting for people with diabetes |
| Francesco | Giorgino | Italy | Addressing glucose patterns in type 2 diabetes: Opportunities and challenges |
| Fernando | Gómez- Peralta | Spain | Connected insulin pens and caps: An expert’s recommendation from the area of diabetes of the Spanish Endocrinology and Nutrition Society (SEEN) |
| Amit | Gupta | India | Challenges and opportunities in digital diabetes care in India |
| Michael | Haller | USA | Cost effectiveness of immune therapies in preserving beta cell function – Real world applications |
| Simon | Heller | UK | Should the classification of hypoglycemia be updated? |
| Irl | Hirsch | USA | What has the GMI taught us about A1C? |
| Roman | Hovorka | UK | Fully closed-loop in type 1 and type 2 diabetes |
| Daria | Igudesman | USA | Diet, microbiome, obesity and type 1 diabetes |
| Peter | Jacobs | USA | Unannounced meal detection algorithms: Can we eliminate manual meal boluses? |
| Laura | Jacobsen | USA | Immune therapy – Predicting responders/non-responders |
| Andrej | Janež | Slovenia | Incretins and taste |
| Johan | Jendle | Sweden | Interoperability of diabetes technology – Regulatory hurdle |
| Morten H | Jensen | Denmark | Adherence through cloud-based personalized treatment for Type 2 diabetes: The ADAPT-T2D project |
| Shashank | Joshi | India | Artificial intelligence in diabetes care |
| Partha | Kar | UK | Widening clinical use of diabetes tech in the UK |
| Neal | Kaufman | USA | The importance and impact of family caregivers on a variety of outcomes for people with diabetes |
| Jothydev | Kesavadev | India | 25 years of telemedicine Vs conventional care in diabetes: assessing vascular complications and quality of life |
| Kamlesh | Khunti | UK | Early intervention for type 2 diabetes in primary care |
| David | Klonoff | USA | Interoperability of diabetes technology – Academic view |
| Anna | Korsgaard Berg | Denmark | Skin problems caused by diabetes devices |
| Jernej | Kovac | Slovenia | Genetic background of obesity |
| Boris | Kovatchev | USA | Neural-Net artificial pancreas |
| Lori | Laffel | USA | Interventions to reduce health disparities in diabetes device use |
| Nebojsa | Lalic | Serbia | Achievement of optimal time in range and glucose variability in pump treated type 1 diabetes patients with diabetic kidney disease |
| John | Leth | Denmark | The potential of open-source software in diabetes research |
| Alon | Liberman | Israel | Real world data from type 1 diabetes clinics |
| David | Maahs | USA | Early CGM initiation in pediatric type 1 diabetes: Equity and logistical considerations from the 4T Study |
| Julia | Mader | Austria | Lipohypertrophy and its effect on glucose control/insulin uptake/causes/detection/training and awareness of HCP and PwD |
| Roberto | Mallone | France | Benign autoimmunity & progression to type 1 diabetes |
| Marco | Marigliano | Italy | Relationships between insulin delivery system, CGM satisfaction and glucometrics |
| Brynn | Marks | USA | Insulin delivery is automated, but the education is not: Mothering diabetes technology users |
| Thomas | Martens | USA | CGM guided insulin management |
| Chantal | Mathieu | Belgium | CGM derived data on weekly insulins |
| Barbara | McGowan | UK | Medical therapies for treatment of obesity |
| Laurel | Messer | USA | Technology pearls for professionals |
| Nicola | Minuto | Italy | Sick days management using AHCL systems in pediatrics: What to do when the algorithm is not enough |
| V | Mohan | India | Innovating to use existing technologies under resourced settings |
| Antoinette | Moran | USA | Impact of CGM in East Africa, research and translation |
| Helen | Murphy | UK | Should everyone with type 1 diabetes be offered closed-loop during pregnancy? |
| Mary | Murphy | UK | What inclusion of quality PRO assessment in clinical trials means to people with diabetes |
| Hamidah | Nabakka | Uganda | Diabetes advocate perspective on diabetes technology in low-income countries |
| Max | Nieuwdorp | The Netherlands | A balanced view on microbiome in obesity |
| Revital | Nimri | Israel | Maximizing glycemic control with automated insulin delivery in young children |
| Kirsten | Nørgaard | Denmark | · Low-dose glucagon to prevent hypoglycemia during exercise |
| · Effects of GLP1 in type 1 diabetes | |||
| Alexander | Olbrechts | Belgium | Interoperability of diabetes technology – A company’s view |
| Rakesh | Parikh | India | Artificial Intelligence in the management of diabetes |
| Anne | Peters | USA | Pod use for closed-loop in T2D |
| Jeremy | Pettus | USA | · With Steven Edelman – Rapid fire interpretations of CGM downloads |
| · Insulin resistance in type 1 diabetes: An underappreciated problem | |||
| Heiko | Peuscher | Germany | A survey on existing open-source projects in diabetes simulation |
| Moshe | Phillip | Israel | From dream to reality – The Automated Insulin Delivery (AID) system |
| Ivana | Rabbone | Italy | Technology in the changing management of diabetes in children |
| Dario | Rahelić | Croatia | Use of CGM in nutrition management in type 2 diabetes |
| Yves | Reznik | France | Closed-loop as home care for type 2 diabetes: The Close study |
| Michael | Rickels | USA | Islet cell therapy vs. closed loop insulin delivery for type 1 diabetes |
| Camillo | Ricordi | USA | From the first-in-human success in stem cell derived Islet Transplantation to a cure for all patients with diabetes: Challenges, requirements, and possible solutions |
| Michael | Riddell | Canada | · CGM guided exercise |
| · Lessons learned from the ongoing type 1 diabetes exercise research Initiative | |||
| Samantha | Roberts | UK | Bringing science into lives: a NICE perspective |
| Teresa | Rodriguez-Calvo | Germany | Role of viruses in pathogenesis of type 1 diabetes |
| Leocadio | Rodríguez Mañas | Spain | Current treatment options for sarcopenia in the context of frail older people with diabetes |
| Julio | Rosenstock | USA | Update on weekly insulin Icodec: The way of the future |
| Banshi | Saboo | India | Welcome and introduction to Dtech symposium |
| Andrea | Scaramuzza | Italy | Real-world data in very young AHCL users – Comparison among different systems |
| Desmond | Schatz | USA | Enhancing our understanding of why type 1 diabetes develops. Lessons learned from organ donors |
| Oliver | Schnell | Germany | What PROs mean in routine clinical care |
| Eleanor | Scott | UK | CGM glucose trajectories associated with large and small for gestational age birthweight |
| Elisabeth | Selvin | USA | · Diabetes and cognitive decline and dementia |
| · Should A1C still be a diagnostic criterion for diabetes in 2024? | |||
| Viral | Shah | USA | GLP-1RA and SGLT in type 1 diabetes |
| Jennifer | Sherr | USA | Teplizumab therapy in the real world |
| Gregg | Simonson | USA | CGM (GMI/TIR) as diabetes quality metrics |
| Alan | Sinclair | UK | Sarcopenia in people living with diabetes |
| Jay | Skyler | USA | Stem cell approaches to type 1 diabetes |
| Darja | Šmigoc Schweiger | Slovenia | Guided management of diabetes in female |
| Tim | Street | UK | Interoperability of diabetes technology – Patient’s view |
| Stuart | Weinzimer | USA | Strategies to facilitate technology use in disadvantaged youth with diabetes |
| Emma | Wilmot | UK | Technology-supported behavior intervention in type 2 diabetes (STAND) |
| Jane | Yardley | Canada | Challenges of exercise in women with type 1 diabetes |
| Yariv | Yogev | Israel | Should all women with diabetes in pregnancy undergo induction of labor at 38 weeks of gestation? |
| Dessi | Zaharieva | USA | Translation of exercise guidelines into practical applications for type 1 diabetes |